Legacy AI grade · Sources dated 2026-07-25. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow
Coenzyme Q10 for Hypertension
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Coenzyme Q10 in Hypertension grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
CoQ10 for hypertension shows at best modest blood-pressure drops in subgroup meta-analyses, but the Cochrane review (PMID 26935713) concluded no clinically significant effect. Later MAs (PMID 36130103 n=1,831; 40495903; 17287847) show ~3-4 mmHg SBP reductions in cardiometabolic subgroups only.
The Cochrane citation incorrectly listed n=50 (actual: 3 trials in review). NCCIH caution and tier C/PWW align with weak, surrogate-only evidence.
Do not treat small BP surrogate changes as proven cardiovascular benefit. CoQ10 remains a borderline adjunct, not first-line hypertension therapy.
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.46
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.456
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension
Finding: Across only 2 poolable RCTs (50 participants), CoQ10 did not significantly change systolic BP (MD -3.68 mmHg, 95% CI -8.86 to 1.49) or diastolic BP (MD -2.03 mmHg, 95% CI -4.86 to 0.81), with moderate-quality evidence of no clinically significant effect.
View on PubMed Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials
Finding: Pooling 26 RCTs (1831 subjects with cardiometabolic disease), CoQ10 significantly lowered systolic BP by -4.77 mmHg (95% CI -6.57 to -2.97) with a U-shaped optimum at 100-200 mg/d (moderate-quality evidence), while the diastolic BP effect was only low-quality.
View on PubMed Effects of coenzyme Q10 administration on blood pressure and heart rate in adults: A systematic review and meta-analysis of randomized controlled trials
Finding: Across 45 RCTs (48 effect sizes), CoQ10 produced a small but significant systolic BP reduction (WMD -3.44 mmHg, 95% CI -5.13 to -1.55, p<0.01) but no significant effect on diastolic BP (WMD -1.13 mmHg, p=0.23) or heart rate (p=0.44).
View on PubMed Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials
Finding: This early meta-analysis of 12 trials (362 patients, mostly open-label/uncontrolled) reported large reductions of up to -17 mmHg systolic and -10 mmHg diastolic, but the effect rested largely on non-randomized data and was not reproduced by the later Cochrane review restricted to RCTs.
View on PubMed Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension
Finding: In 83 patients, the CoQ10 group showed a mean systolic BP reduction of -17.8 ± 7.3 mmHg over 12 weeks, but this single small trial was later judged at high risk of bias and excluded from the Cochrane pooled analysis.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
not generally recognized as safe and effective for the referenced uses and therefore are considered "new drugs" source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established between the consumption of coenzyme Q10 and the claimed effects source↗
L4c UK NHS
Cautious
Advise people with migraine that the food supplement riboflavin (400 mg once a day) may be effective in reducing migraine frequency and intensity for some people. source↗
L4d TW TFDA / 衛福部
Cautious
訂定「食品原料輔酵素Q10 (Coenzyme Q10)之使用限制及標示規定」 source↗
L5b Mayo Clinic
Cautious
Although findings are mixed, CoQ10 might help lower blood pressure. source↗
L5c Cleveland Clinic
Cautious
CoQ10 can lower blood pressure, so it may not be appropriate to take it if you're on blood pressure medication that also drives those numbers down. source↗
L5e Specialty Society (condition-mapped)
Cautious
CoQ10 may interact with blood pressure medications and the blood thinner warfarin. However, the benefits of CoQ10 are not clear, and more research is needed. source↗